Likewise, the positive results from clinical trials led to the approval of pembrolizumab in combination with pemetrexed and platinum chemotherapy as a 1L therapy in patients with non-squamous NSCLC in adults whose tumors had PD-L1 <50% and who had developed no EGFR- or ALK-positive mutations since January 2020 in the Emilia-Romagna region. The gene discussed is ALK; the disease is non-small cell lung carcinoma.